Overview Submission Instructions Recent Publications Frequently Asked Questions Research Topics

Looking to publish in Molecular Therapy Nucleic Acids? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now

Molecular Therapy Nucleic Acids

Molecular Therapy Nucleic Acids is an international open-access journal and an official journal of the American Society of Gene & Cell Therapy. It publishes basic, translational, and clinical research, reviews, and commentaries focused on nucleic-acid-based therapeutics for genetic and acquired disease, including areas such as RNA-based therapeutics, delivery vectors, gene-modifying agents, preclinical validation, safety and efficacy studies, and clinical trials.

Looking to publish in Molecular Therapy Nucleic Acids? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now

Subject Medicine, Research & Experimental

Impact Factor 6.1

Quartile Q1

Open Access Type Open

ISSN 2162-2531

eISSN 2162-2531

Invitation Only No

Cost Range $3,900 excluding taxes; society member discount: $3,120

Submission Instructions

Molecular Therapy Nucleic Acids accepts the following article types. Click on an article type to view submission instructions.

Original Research Article

Cover Letter A cover letter on institutional letterhead is required. The cover letter must explain the conceptual advance and relevance to readers, include handling information such as related work or time constraints, and declare financial conflicts of interest.

Abstract An unstructured abstract is required. Abstract must not exceed 200 words. Abstract must be unstructured and written as a single paragraph.

Manuscript Manuscript must be organized as abstract, introduction, results, discussion, materials & methods, data availability statement, acknowledgments, author contributions, declaration of interests statement, 5-10 keywords, references, tables, and a list of figure legends, and the results and discussion sections must not be combined. Manuscript must include 5-10 keywords, an author contributions section, a declaration of interests statement, a data availability statement, and a declaration of generative AI and AI-assisted technologies in the writing process at the end of the manuscript before the references if such tools were used.

References References must include only published or in-press items, be cited in superscript numerical order of appearance, be listed numerically with figure-legend and table-only citations after text citations, and list the first ten authors followed by et al. when there are more than ten authors.

Figures & Tables Original Research Articles may include no more than 8 display items total across figures and tables, with additional display items allowed as supplemental material. For first-round review, figures may be included after the tables in the manuscript file or interspersed with figure legends within the manuscript, and high-resolution figure files must also be uploaded separately when submitted. Manuscript must include a graphical abstract/eTOC, the graphical abstract must be an illustration without original data images and uploaded under the Graphical Abstract category in TIFF, PDF, or JPEG format, and tables must appear at the end of the manuscript with a list of figure captions after the references.

Reformat to Molecular Therapy Nucleic Acids using Livewrite Premium

Review Article

Cover Letter A cover letter on institutional letterhead is required. Cover letter must explain the conceptual advance and relevance to readers, notify any information relevant to handling and evaluation, and declare financial conflicts of interest.

Abstract An abstract is required. Abstract must be unstructured and no more than 200 words. Abstract must be unstructured. Abstract must not include headings.

Manuscript Review Article manuscripts are limited to a maximum of 5 authors. Manuscript must be organized as introduction, text, acknowledgments, author contributions, declaration of interest statement, 5-10 keywords, references, tables, and a list of figure legends. Manuscript must include 5-10 keywords, an author contributions section, a declaration of interest statement, and a Declaration of Generative AI and AI-assisted technologies in the writing process section before the references if such tools were used.

References References must be cited in numerical order as superscripts after punctuation, listed in numerical order, include only published or in-press works, list the first ten authors followed by et al. when there are more than ten, and use PubMed journal abbreviations.

Figures & Tables Review Article manuscripts must include no more than 8 display items total across figures and tables. For first-round review, figures may be included after the tables in the manuscript file or uploaded separately, and tables must be presented at the end of the manuscript. Submission must include a graphical abstract/eTOC as an illustration without original data images, uploaded under the Graphical Abstract category in TIFF, PDF, or JPEG format.

Reformat to Molecular Therapy Nucleic Acids using Livewrite Premium

Brief Report

Cover Letter A cover letter on institutional letterhead is required. Cover letter must explain the conceptual advance and relevance to readers and include information relevant to handling and evaluation of the paper.

Abstract An abstract is required. Abstract must be unstructured and no more than 200 words. Abstract must be unstructured.

Manuscript Manuscript must not exceed 4,000 words excluding disclosures and references. Manuscript must be organized as abstract, introduction, results, discussion, materials & methods, data availability statement, acknowledgments, author contributions, declaration of interest statement, 5-10 keywords, references, tables, and a list of figure legends. Manuscript must include 5–10 keywords, an author contributions section, a declaration of generative AI and AI-assisted technologies in the writing process at the end of the core manuscript before the references if applicable, and a graphical abstract/eTOC.

References References must not exceed 30. References must be cited numerically in order of appearance, with superscript citations placed after punctuation, and references with more than ten authors must list the first ten followed by et al.

Figures & Tables Manuscript must include no more than 3 display items total across figures and tables. For first-round review, figures may be included after the tables in the manuscript file. The manuscript must include a list of figure legends and tables at the end, with figures and tables numbered sequentially in Arabic numerals.

Reformat to Molecular Therapy Nucleic Acids using Livewrite Premium

Letter To The Editor

Abstract Abstract requirements are not specified.

Manuscript Letter To The Editor manuscripts must not exceed 1200 words, excluding disclosures and references. Letter To The Editor manuscripts must not include display items, must not present unpublished data in support of the author's position, and any use of generative AI in writing must be disclosed in a declaration section before the references.

References Letter To The Editor manuscripts may include a maximum of 10 references. References must be cited in numerical order as superscripts placed after punctuation, and the reference list must be arranged numerically with only published or in-press items included.

Figures & Tables Letter To The Editor manuscripts must not include display items.

Reformat to Molecular Therapy Nucleic Acids using Livewrite Premium

Recent Publications

Optimizing C14120-based lipid nanoparticles for mRNA delivery: Editorial commentary

Vincent Fung, Caroline Argenti, Maggie Magaw, Owen S. Fenton

10.1016/j.omtn.2026.102945

View Publication

Multiscale Modeling Guided Potency Assessment of mRNA-Lipid Nanoparticles

Yuling Yang, Yuchen Qiu, Keqi Wang, Yifang Liu, Gautam Sanyal, Paul C. Whitford, Sara H. Rouhanifard, Wei Xie

10.1016/j.omtn.2026.102965

View Publication

CD39 mRNA Therapy Attenuates Localized Acute Inflammation: A Novel Anti-Inflammatory Strategy using Cationic Nanoliposomes

Naomi R. Philosof, Aidan P.G. Walsh, Bangyan Xu, Anna M.D. Watson, Shulei Ren, Ludmilla Hann, Benedict Nathaniel, Anne Nguyen, Haikun Liu, Pengkai Shi, Viktoria Bongcaron, Hung Nguyen, Jonathan Noonan, Meltem Avci-Adali, Karlheinz Peter, Mark Louis P. Vidallon, Xiaowei Wang

10.1016/j.omtn.2026.102966

View Publication

Cell Type–Stratified Immunogenetic Framework Reveals Immune Drivers and Therapeutic Targets in Kidney Stone Disease

Dianjie Zeng, Lingfei Zhu, Jiachen Liu, Xiaorui Qiu, Leyi Chen, Chenming Wei, Yinhuai Wang, Zebin Deng

10.1016/j.omtn.2026.102964

View Publication

Developing a pan cancer therapy based on DISE inducing short RNAs

Andrea E. Murmann, Mehrnoosh Ebadi, Monal Patel, Alexander Ewe, Sergio Barajas, Shiyu Xiao, Min Jun Ko, Sanghee Lee, Wenjie Cai, Bidur Paudel, Limin Sun, Elizabeth T. Bartom, Masha Kocherginsky, Yan Liu, Dong-Hyun Kim, Achim Aigner, Marcus E. Peter

10.1016/j.omtn.2026.102963

View Publication

Frequently asked questions

How long does it take to publish?

Accepted materials are posted online within 3-5 business days of beginning production. Accepted manuscripts are usually published online within two days of formal acceptance. Corrected articles are typically posted online 5-7 business days after corrections are received, and proof corrections are due within 48 hours.

Reformat to Molecular Therapy Nucleic Acids using Livewrite Premium

Is a cover letter required?

A cover letter is required on institutional letterhead. It should explain the conceptual advance and relevance to readers and disclose information relevant to editorial handling, including related work, time constraints, competition, and fast-track status when applicable.

Reformat to Molecular Therapy Nucleic Acids using Livewrite Premium

What are the publication costs?

$3,900 excluding taxes; society member discount: $3,120

Reformat to Molecular Therapy Nucleic Acids using Livewrite Premium

Research Topics

RNA Interference and Gene Delivery MicroRNA in disease regulation Cancer-related molecular mechanisms research CRISPR and Genetic Engineering Circular RNAs in diseases Advanced biosensing and bioanalysis techniques RNA modifications and cancer RNA Research and Splicing Virus-based gene therapy research RNA and protein synthesis mechanisms RNA regulation and disease Extracellular vesicles in disease Muscle Physiology and Disorders DNA and Nucleic Acid Chemistry interferon and immune responses Immunotherapy and Immune Responses Pluripotent Stem Cells Research Epigenetics and DNA Methylation Neurogenetic and Muscular Disorders Research Retinal Development and Disorders Cancer-related gene regulation Genetic Neurodegenerative Diseases Viral Infections and Immunology Research CAR-T cell therapy research HIV Research and Treatment

Related Journals

Life Medicine Oxford University Press

Medcomm WILEY

Cancer Gene Therapy Springer Nature

Molecular Aspects Of Medicine Elsevier BV

Journal Of Experimental Medicine Rockefeller University Press

Journal Of Translational Medicine BioMed Central